At UCB, the goal is to develop and produce medicines for people with severe diseases in the most environmentally and sustainable way possible. In innovation and in the development of new products, UCB considers not only the benefits of its products but also the potential health and environmental risks. The company aims to render its operations carbon neutral by 2030 and has invested €500,000 in a cryocondenser for the development of a new production process to avoid any atmospheric emissions of volatile organic components.
Cryocondensation is a recognised best available technique to remove solvent vapours from gaseous emissions, based on the principle of condensing gases into liquids by reducing the temperature of the gaseous emissions using a cooling medium such as liquid nitrogen, and thus eliminating atmospheric emissions. UCB has found a second use for the solvents recovered at the cryocondenser’s outlet, in a specialized treatment centre where they use the recovered liquids as a resource of chlorine. This illustrates UCB’s desire to manage its activities in a sustainable manner through a life-cycle approach.
Source : UCB Braine-l’Alleud